Support Maps
MAPS’ mission is to treat conditions for which conventional medicines provide limited relief, such as PTSD & anxiety associated with life-threatening illnesses, by developing psychedelics & marijuana into prescription medicines.
First LSD Study in 35 Years Treats Last Subject:
MAPS E-Mail Newsletter
June 9, 2011

Dear xxxx,
Summer is fast approaching. The days are getting longer, the breeze is getting warmer, and the only thing that’s growing faster than the roses in my garden is MAPS’ clinical research program.In the past month, new studies of MDMA-assisted psychotherapy for PTSD were approved by government agencies in both Israel and the United States. We also finalized the data for our Swiss study of MDMA-assisted psychotherapy for PTSD, Health Canada completed its inspection of our Vancouver study facilities, and we began planning for a study of ibogaine treatment for addiction in New Zealand.

MAPS is now planning or conducting research in six countries and on four continents. As a worldwide leader in psychedelic psychotherapy research, we have a responsibility to ensure the clarity, consistency, and reliability of our treatment approach.

Donate Make a Contribution

Setting standards for treatment, developing training manuals, and making research tools accessible to researchers around the world are all part of how MAPS is helping bring psychedelic healing to those who need it most.

On May 26, the last subject was treated in our Swiss study of LSD-assisted psychotherapy for anxiety due to life-threatening illness—the first clinical LSD study in over 35 years.

Psychiatrist and lead investigator Peter Gasser, M.D., indicated in a letter to friends and colleagues that he was deeply moved by the changes he witnessed in his subjects after undergoing treatment with LSD-assisted psychotherapy. He believes that the treatment helped some of them overcome the sense of isolation and despair that often comes with confronting death.

One subject reported that she wanted to clap “the warm buttocks of a cow” once more before she died as a symbol of reconnecting to something solid, familiar, and full of life. “In the second LSD session, she was dancing and singing in the treatment room, something she always wanted to do but never dared to do in her whole life.”

It’s still too early to report the final results of this study, but the fact that not a single subject had a serious negative reaction to the treatment is a major accomplishment that opens the door to future LSD psychotherapy research.

In this edition of the MAPS E-mail Newsletter, learn how we’re expanding our research program, internationalizing our efforts, and planning for the future of psychedelic medicine.

None of our accomplishments would have been possible without our members. We need your support more than ever.


Brad Burge, M.A.
MAPS Director of Communications

MDMA Research News:

  1. Israeli Ministry of Health Approves MDMA/PTSD Study
  2. FDA Approves New MDMA/PTSD Relapse Study
  3. Data Finalized for Swiss MDMA/PTSD Study
  4. Health Canada Completes Pharmacy Inspection for Canadian MDMA/PTSD Study
  5. First Subject Unblinded in US MDMA/PTSD Veterans Study
  6. Training Manual Completed for Independent Raters in MDMA/PTSD Studies
  7. PTSD Diagnostic Scale Translated for Middle East MDMA/PTSD Studies

Other Research News:

  1. Last Subject Treated in Swiss Study of LSD-Assisted Psychotherapy for End-of-Life Anxiety
  2. New Study of Ibogaine Treatment for Addiction Planned for New Zealand
  3. UK Researchers Seek Participants for Drug Experience Survey

Fundraising News:

  1. Wellcome Trust Considers Accepting Grant Application for UK MDMA/PTSD Study; May Convene Advisory Meeting


  1. Psychiatric Times: Does MDMA Have a Role in Clinical Psychiatry?
  2. American Botanical Council: FDA Accepts Protocol for Study on Marijuana and PTSD
  3. Cell: Cannabinoid System Offers New Therapeutic Possibilities and Challenges


  1. Details Announced for MAPS Canada Benefit Events This Fall
  2. MAPS Discusses Psychedelic Research and Education with Student Activists
  3. European Ayahuasca Research Symposium Convenes in Amsterdam June 17
  4. Special MAPS Discount for 2011 Science and Nonduality Conference This October
  5. Speakers Announced for Horizons Psychedelics Conference in NYC

Support Maps
MAPS’ mission is to treat conditions for which conventional medicines provide limited relief, such as PTSD & anxiety associated with life-threatening illnesses, by developing psychedelics & marijuana into prescription medicines.
Middle East MDMA/PTSD Studies Move Forward:
MAPS News Update
March 9, 2011

Sometimes in small steps and sometimes in great leaps, psychedelics and marijuana are returning to mainstream science and medicine. For a quarter century, our members and supporters have been enabling MAPS to change how the world thinks about these substances by providing honest education about their risks and benefits through rigorous research. In this edition of the MAPS e-mail newsletter, I share with you the latest news from the frontier.

Donate Make a Contribution

Our new Israeli study of MDMA-assisted psychotherapy for PTSD is poised to move forward as we prepare the latest revision for submission to the Israeli Ministry of Health. Our clinical research team also completed an intensive 5-day training course for the therapists who will be conducting the experimental sessions, ensuring that subjects receive the best support possible for their treatment. Our Jordanian MDMA/PTSD clinical team had a tremendously successful investigators’ meeting as the study awaits the final approval of the Jordanian Food and Drug Administration. Our Swiss MDMA/PTSD study has now officially ended, but the work is far from over: Now it’s time to analyze the data and prepare it for publication.

I’m also excited to announce that we have made huge progress in getting regulatory approval for our proposed study of smoked and/or vaporized marijuana for veterans with PTSD. On February 9, in an immensely productive teleconference, the U.S. Food and Drug Administration informed us that they were satisfied with our responses to their prior concerns about the study and are likely to approve the revised protocol. Of course, this is hardly the end of our efforts to get this innovative marijuana study off the ground. The study still has to pass the redundant and obstructive Public Health Service/National Institute on Drug Abuse review process, but we hope that they’ll follow the FDA’s lead and recognize that when it comes to clinical research, we know what we’re doing.

Unfortunately, the DEA has other priorities. On March 7, the final brief was submitted in MAPS and Professor Lyle Craker’s decade-long lawsuit against the DEA to start our own medical marijuana farm and break NIDA’s monopoly on marijuana for research. The federal government’s research blockade continues to keep medicine out of the hands of patients, and we’re not backing down.

The progress MAPS is making in the domain of science has not escaped the attention of the mainstream media. In the last month, MAPS’ MDMA/PTSD research has received over 25 media mentions, including a breathtaking and sympathetic cover article in Oprah Winfrey’s O Magazine in which journalist (and O Magazine senior editor) Jessica Winter shares her own experience of MDMA-assisted psychotherapy. This is about as mainstream as it gets. The psychedelic research frontier feels less frontier-like every day.

I want to thank all of you who have already participated in our “Watch, Learn, & Share” video campaign for bringing us to within $2000 of our $15,000 fundraising goal. If you haven’t yet, make sure to visit the MAPS website and watch one of the videos from our 2010 “Psychedelic Science in the 21st Century” conference. A generous donor has agreed to contribute $1 to MAPS every time a video is watched—so by viewing one of these videos now you can both learn from the world’s foremost experts on psychedelic science and medicine and help MAPS achieve its goals.

As always, I remind you that MAPS is much more than a collection of scientists and therapists: It’s an entire community of people like you who recognize the value of careful scientific research and the capacity of psychedelics to heal our minds and bodies. Please contribute today.


Brad Burge, M.A.
MAPS Communication and Education Associate